These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 36053283)

  • 1. Prediction of the pharmacokinetics of pemetrexed with a low test dose: A proof-of-concept study.
    Boosman RJ; de Rouw N; Huitema ADR; Burgers JA; Ter Heine R
    Br J Clin Pharmacol; 2023 Feb; 89(2):699-704. PubMed ID: 36053283
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetically-guided dosing of pemetrexed in a patient with renal impairment and a patient requiring hemodialysis.
    de Rouw N; Croes S; Posthuma R; Agterhuis DE; Schoenmaekers JJAO; Derijks HJ; Burger DM; Dingemans AM; Ter Heine R
    Lung Cancer; 2019 Apr; 130():156-158. PubMed ID: 30885337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A limited sampling schedule to estimate individual pharmacokinetics of pemetrexed in patients with varying renal functions.
    de Rouw N; Visser S; Koolen SLW; Aerts JGJV; van den Heuvel MM; Derijks HJ; Burger DM; Ter Heine R
    Cancer Chemother Pharmacol; 2020 Jan; 85(1):231-235. PubMed ID: 31853639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rethinking the Application of Pemetrexed for Patients with Renal Impairment: A Pharmacokinetic Analysis.
    de Rouw N; Boosman RJ; Huitema ADR; Hilbrands LB; Svensson EM; Derijks HJ; van den Heuvel MM; Burger DM; Ter Heine R
    Clin Pharmacokinet; 2021 May; 60(5):649-654. PubMed ID: 33420970
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population Pharmacokinetics of Pemetrexed in Adult Non-Small Cell Lung Cancer in Indian Patients.
    Srinivasan M; Chaturvedula A; Fossler MJ; Patil A; Gota V; Prabhash K
    J Clin Pharmacol; 2019 Sep; 59(9):1216-1224. PubMed ID: 30973978
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II evaluation of LY2603618, a first-generation CHK1 inhibitor, in combination with pemetrexed in patients with advanced or metastatic non-small cell lung cancer.
    Scagliotti G; Kang JH; Smith D; Rosenberg R; Park K; Kim SW; Su WC; Boyd TE; Richards DA; Novello S; Hynes SM; Myrand SP; Lin J; Smyth EN; Wijayawardana S; Lin AB; Pinder-Schenck M
    Invest New Drugs; 2016 Oct; 34(5):625-35. PubMed ID: 27350064
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pemetrexed exposure predicts toxicity in advanced non-small-cell lung cancer: A prospective cohort study.
    Visser S; Koolen SLW; de Bruijn P; Belderbos HNA; Cornelissen R; Mathijssen RHJ; Stricker BH; Aerts JGJV
    Eur J Cancer; 2019 Nov; 121():64-73. PubMed ID: 31561135
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Toxicity of pemetrexed during renal impairment explained-Implications for safe treatment.
    Boosman RJ; Dorlo TPC; de Rouw N; Burgers JA; Dingemans AC; van den Heuvel MM; Hendriks LEL; Biesma B; Aerts JGJV; Croes S; Mathijssen RHJ; Huitema ADR; Ter Heine R
    Int J Cancer; 2021 Oct; 149(8):1576-1584. PubMed ID: 34181276
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pemetrexed safety and pharmacokinetics in patients with third-space fluid.
    Dickgreber NJ; Sorensen JB; Paz-Ares LG; Schytte TK; Latz JE; Schneck KB; Yuan Z; Sanchez-Torres JM
    Clin Cancer Res; 2010 May; 16(10):2872-80. PubMed ID: 20460481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hyperhydration with cisplatin does not influence pemetrexed exposure.
    de Rouw N; Derijks HJ; Hilbrands LB; Boosman RJ; Piet B; Koolen SLW; Burgers JA; Dingemans AC; van den Heuvel MM; Hendriks LEL; Aerts JGJV; Croes S; Mathijssen RHJ; Huitema ADR; Burger DM; Biesma B; Ter Heine R
    Br J Clin Pharmacol; 2022 Feb; 88(2):871-876. PubMed ID: 34374116
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Highly sensitive quantification of pemetrexed in human plasma using UPLC-MS/MS to support microdosing studies.
    van Ewijk-Beneken Kolmer EWJ; Teulen MJA; Boosman RJ; de Rouw N; Burgers JA; Ter Heine R
    Biomed Chromatogr; 2022 Feb; 36(2):e5277. PubMed ID: 34741344
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I study of nintedanib in combination with pemetrexed as second-line treatment of Japanese patients with advanced non-small cell lung cancer.
    Daga H; Takeda K; Okada H; Miyazaki M; Ueda S; Kaneda H; Okamoto I; Yoh K; Goto K; Konishi K; Sarashina A; Tanaka T; Kaiser R; Nakagawa K
    Cancer Chemother Pharmacol; 2015 Dec; 76(6):1225-33. PubMed ID: 26560486
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Comparative Pharmacokinetic Study of 2 Pemetrexed Formulations in Indian Adult Chemonaive Patients With Adenocarcinoma Stage III/IV Non-Small Cell Lung Cancer.
    Kavathiya K; Gurjar M; Patil A; Naik M; Noronha V; Joshi A; Gota V; Prabhash K
    Clin Pharmacol Drug Dev; 2017 May; 6(3):234-239. PubMed ID: 28371303
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Renal function-based versus standard dosing of pemetrexed: a randomized controlled trial.
    de Rouw N; Boosman RJ; Burgers JA; Huitema ADR; Dingemans AC; Derijks HJ; Burger DM; Piet B; Hendriks LEL; Biesma B; Pruis MA; Dumoulin DW; Croes S; Mathijssen RHJ; van den Heuvel MM; Ter Heine R
    Cancer Chemother Pharmacol; 2023 Jan; 91(1):33-42. PubMed ID: 36413252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Limited sampling models and Bayesian estimation for mycophenolic acid area under the curve prediction in stable renal transplant patients co-medicated with ciclosporin or sirolimus.
    Musuamba FT; Rousseau A; Bosmans JL; Senessael JJ; Cumps J; Marquet P; Wallemacq P; Verbeeck RK
    Clin Pharmacokinet; 2009; 48(11):745-58. PubMed ID: 19817503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and the effect of heat on intraperitoneal pemetrexed using a murine model.
    Badrudin D; Perrault-Mercier C; Bouchard-Fortier A; Hubert J; Leblond FA; Sideris L; Dubé P
    Surg Oncol; 2016 Dec; 25(4):435-440. PubMed ID: 27251757
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial.
    Zalcman G; Mazieres J; Margery J; Greillier L; Audigier-Valette C; Moro-Sibilot D; Molinier O; Corre R; Monnet I; Gounant V; Rivière F; Janicot H; Gervais R; Locher C; Milleron B; Tran Q; Lebitasy MP; Morin F; Creveuil C; Parienti JJ; Scherpereel A;
    Lancet; 2016 Apr; 387(10026):1405-1414. PubMed ID: 26719230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I and pharmacokinetic study of pemetrexed plus cisplatin in chemonaive patients with locally advanced or metastatic malignant pleural mesothelioma or non-small cell lung cancer.
    Dickgreber NJ; Fink TH; Latz JE; Hossain AM; Musib LC; Thomas M
    Clin Cancer Res; 2009 Jan; 15(1):382-9. PubMed ID: 19118069
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population pharmacokinetic analysis of ten phase II clinical trials of pemetrexed in cancer patients.
    Latz JE; Chaudhary A; Ghosh A; Johnson RD
    Cancer Chemother Pharmacol; 2006 Apr; 57(4):401-11. PubMed ID: 16322991
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Encapsulation in a rapid-release liposomal formulation enhances the anti-tumor efficacy of pemetrexed in a murine solid mesothelioma-xenograft model.
    Eldin NE; Abu Lila AS; Kawazoe K; Elnahas HM; Mahdy MA; Ishida T
    Eur J Pharm Sci; 2016 Jan; 81():60-6. PubMed ID: 26415830
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.